Europeans ‘should get on with Oxford-astrazenica vaccine’ after new data

EUROPEAN countries should “get on” with using the Oxfordastrazeneca vaccine in elderly people to save lives, a member of the Joint Committee on Vaccination and Immunisation (JCVI) has said, as a new study found that a single dose gives remarkable protection.

Adam Finn, professor of paediatrics at the University of Bristol, presented new research on people over the age of 80 which found that one shot of either the Pfizer-biontech or Oxford vaccine prevented severe disease that would lead to hospital admission.

Urging other countries to use their stocks of the Oxford jab, he told a briefing: “The UK is well forward, this age group have been immunised now, we’re down into people in their 60s, we’ve achieved 90 per cent uptake.

“In the short term, the job’s done in the United Kingdom. But there are lots of doses of Astrazeneca vaccine available in European countries, and they are not being given to people over the age of 65, in some cases in countries over the age of 55, for lack of data.

“Well, here are the data.

“There are data from Public Health England and Scotland and now from us, showing that you can save lives in elderly people by giving them a dose of Astrazeneca vaccine.

“And those countries need to get on and start doing that as fast as possible.”

The new study led by Prof Finn involved elderly adults with pneumonia, Covid or another acute respiratory infection.

It included 466 adults over 80, many of whom had other health problems and with around 90% regarded as frail. The findings showed that one dose of Pfizer was 79.3% effective from 14 days after inoculation at preventing illness severe enough to require hospital admission.

Looking at the same time period, a single dose of the Oxfordastrazeneca vaccine was 80.4% effective against the same level of illness in the same group, also from 14 days after vaccination.